XML 27 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Operating activities      
Net Loss $ (189,304) $ (134,702) $ (465,264)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:      
Credit loss expense 6,106 1,704 2,399
Depreciation and amortization 25,689 26,460 37,544
Amortization of financing costs charged to interest expense 1,633 1,648 1,595
Amortization of right-of-use asset 2,187 3,055 6,196
Impairment of goodwill and intangible assets 131,595 70,518 453,288
Loss on divestiture 0 6,550 0
Accretion of debt discount and non-cash interest expense (13,017) 0 0
Stock-based compensation expense 40,367 40,980 44,686
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability 210 1,246 (128,174)
Other non-cash expense (income), net 1,481 (4,170) 6,589
Income tax benefit 0 0 (1,446)
Increase (Decrease) in Operating Capital [Abstract]      
Accounts receivable and contracts assets, net 12,497 (7,725) (4,546)
Prepaid expenses and other assets 1,360 2,492 535
Accounts payable 499 239 (893)
Other accrued expenses (6,644) (7,492) (9,516)
Partner Share liability (16,350) 405 1,721
Customer Incentive liability (7,133) (1,393) 1,382
Net cash used in operating activities (8,824) (185) (53,904)
Investing activities      
Acquisition of property and equipment (1,562) (667) (1,171)
Acquisition of patents 0 0 (175)
Capitalized software development costs (17,736) (11,725) (12,140)
Business acquisitions, net of cash acquired 0 0 (2,274)
Proceeds from Divestiture of Businesses, Net of Cash Divested 552 2,330 0
Net cash used in investing activities (18,746) (10,062) (15,760)
Financing activities      
Proceeds from issuance of debt 172,500 30,000 0
Principal payments of debt (199,303) (31) (35)
Proceeds from termination of capped calls related to convertible notes 115 0 0
Proceeds from issuance of common stock 48,645 55 379
Settlement of contingent consideration (14,167) (50,050) 0
Repurchase of common stock 0 0 (40,000)
Equity issuance costs (309) 0 (157)
Debt issuance costs (6,037) 0 (174)
Net cash provided by (used in) financing activities 1,444 (20,026) (39,987)
Effect of exchange rates on cash, cash equivalents and restricted cash (110) 118 (1,926)
Net decrease in cash, cash equivalents and restricted cash (26,236) (30,155) (111,577)
Cash, cash equivalents, and restricted cash — Beginning of period 91,830 121,985 233,562
Cash, cash equivalents, and restricted cash — End of period 65,594 91,830 121,985
Cash and cash equivalents 65,594 91,830 121,905
Restricted cash 0 0 80
Total cash, cash equivalents and restricted cash — End of period 65,594 91,830 121,985
Supplemental schedule of non-cash investing and financing activities:      
Cash paid for interest 6,119 4,240 2,381
Amounts accrued for property and equipment 95 579 67
Amounts accrued for capitalized software development costs 174 40 155
Issuance of common stock, net of issuance costs - Settlement Agreement (as defined below) $ 27,451 $ 0 $ 0